Tracking of appendicular bone mineral density for 6 years including the pubertal growth spurt: Japanese Population-based Osteoporosis Kids Cohort Study

被引:0
作者
Yuki Fujita
Masayuki Iki
Yukihiro Ikeda
Akemi Morita
Tomoharu Matsukura
Harumi Nishino
Takashi Yamagami
Sadanobu Kagamimori
Yoshiko Kagawa
Hideo Yoneshima
机构
[1] Kinki University,Department of Public Health, Faculty of Medicine
[2] Kinki University Hospital,Department of Centre for Occupational Safety and Health Management
[3] National Institute of Health and Nutrition,Nutritional Education Program
[4] Toyama Prefectural Government,undefined
[5] Toyama Pharmaceutical Association,undefined
[6] Hokuriku Health Service Association,undefined
[7] University of Toyama,undefined
[8] Kagawa Nutrition University,undefined
[9] Shuuwa General Hospital,undefined
来源
Journal of Bone and Mineral Metabolism | 2011年 / 29卷
关键词
Biological markers; Bone density; Bone development; Puberty;
D O I
暂无
中图分类号
学科分类号
摘要
Bone development up to early adulthood plays an important role in determining the risk of osteoporosis later in life. However, bone development in children has not been fully documented by longitudinal studies in Japanese children. The purpose of this study is to determine the degree of tracking of areal bone mineral density (aBMD) from pre-puberty to 6-year follow-up, and to determine the target period to achieve maximal peak aBMD. This study was conducted as the pediatric part of a larger cohort study, the Japanese Population-based Osteoporosis (JPOS) study. Of 448 children aged 9–12 years who completed the baseline survey, 225 participated in the follow-up study 6 years later (follow-up rate: 50.2%). aBMD at the forearm was measured using dual-energy X-ray absorptiometry. aBMD values in pre-pubertal children at baseline showed a significant tracking correlation with aBMD obtained at 6-year follow-up in both genders (boys r = 0.655, girls r = 0.759). Although boys and girls in the lowest quartile of aBMD pre-pubertally had greater annual increases in aBMD from pre-puberty to 6-year follow-up than those in other aBMD quartiles, they still showed the lowest mean aBMD at 6-year follow-up. Children with lower pre-pubertal aBMD showed greater increases in BMD up until 6-year follow-up, but the increase was not great enough to catch up with other children. About 50% of the variance in aBMD at 6-year follow-up was determined by the aBMD achieved during the pre-pubertal period. Activities that increase aBMD are important not only for children during puberty, but also for younger pre-pubertal children.
引用
收藏
页码:208 / 216
页数:8
相关论文
共 173 条
  • [1] van der Klift M(2004)Risk factors for incident vertebral fractures in men and women: the Rotterdam Study J Bone Miner Res 19 1172-1180
  • [2] de Laet CE(2007)Risk factors and prevention of osteoporosis-related fractures J Musculoskelet Neuronal Interact 7 268-272
  • [3] McCloskey EV(2000)Peak bone mass Osteoporos Int 11 985-1009
  • [4] Johnell O(1999)Bone growth from 11 to 17 years: relationship to growth, gender and changes with pubertal status including timing of menarche Acta Paediatr 88 139-146
  • [5] Kanis JA(2009)Tracking of bone mass from childhood to adolescence and factors that predict deviation from tracking Bone 44 752-757
  • [6] Hofman A(1998)Familial resemblance for bone mineral mass is expressed before puberty J Clin Endocrinol Metab 83 358-361
  • [7] Pols HA(2000)Reference data of forearm bone mineral density in healthy Japanese male and female subjects in the second decade based on calendar age and puberty onset: Japanese Population Based Osteoporosis (JPOS) study Osteoporos Int 11 858-865
  • [8] Dontas IA(1990)Serum levels of BGP determined by two-site immunoradiometric assay (IRMA) using monoclonal antibodies Clin Endocrinol 38 1291-1296
  • [9] Yiannakopoulos CK(1993)Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease J Clin Endocrinol Metab 77 1046-1053
  • [10] Heaney RP(1987)Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia Clin Chem 33 1364-1367